Liquid Biopsy for Breast Cancer Biomarkers Discovery
Clotilde Costa,
Leader of the Liquid Biopsy Line,
Joint Unit Roche-Chus, Oncomet, Universitary Cinical Hospital of Santiago de Compostela
Metastasis is responsible for 90% of cancer related deaths, thus, biomarkers discovery to predict and monitor tumor progression is an urgent need in oncology. Liquid Biopsy analysis permit to obtain tumoral information in real time, in a non-invasive way and in a systemic manner. Thus, molecular characterization of circulating material of metastatic breast cancer patients in different time points of the disease (before and after treatment) had led us to identify biomarkers with interest for clinical oncology translation.
|
|
